Evidence map›Paper›PMID 29709847›Full record

ArticleThe International journal on drug policy2018

Big data on a big new market: Insights from Washington State's legal cannabis market.

Jonathan P Caulkins, Yilun Bao, Steve Davenport, Imane Fahli, Yutian Guo, Krista Kinnard, Mary Najewicz, Lauren Renaud, Beau Kilmer

Abstract read
In one paragraph

Article in The International journal on drug policy, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.

0numbers the graph read from it
0cells of the map it votes in
22citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

22 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Patient out-of-pocket costs for cannabis use during cancer treatment.Journal of the National Cancer Institute. Monographs · 2024
    Article
  5. Article
  6. Article
  7. Self-reported knowledge of tetrahydrocannabinol and cannabidiol concentration in cannabis products among cancer patients and survivors.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2024
    Article
  8. Article
  9. Article
  10. Article
  11. Ultraviolet radiation exposure in cannabis-growing facilities.Journal of occupational and environmental hygiene · 2023
    Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. GEOGRAPHICAL ACCESS TO RECREATIONAL MARIJUANA.Contemporary economic policy · 2021
    Article
  18. Article
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Jonathan P CaulkinsCarnegie Mellon University Heinz College, 5000 Forbes Ave., Pittsburgh PA 15213, USA. Electronic address: caulkins@andrew.cmu.edu.
Yilun BaoCarnegie Mellon University Heinz College, 5000 Forbes Ave., Pittsburgh PA 15213, USA.
Steve DavenportRAND Drug Policy Research Center, 1776 Main St., Santa Monica, CA 90401, USA.
Imane FahliCarnegie Mellon University Heinz College, 5000 Forbes Ave., Pittsburgh PA 15213, USA.
Yutian GuoCarnegie Mellon University Heinz College, 5000 Forbes Ave., Pittsburgh PA 15213, USA.
Krista KinnardCarnegie Mellon University Heinz College, 5000 Forbes Ave., Pittsburgh PA 15213, USA.
Mary NajewiczCarnegie Mellon University Heinz College, 5000 Forbes Ave., Pittsburgh PA 15213, USA.
Lauren RenaudCarnegie Mellon University Heinz College, 5000 Forbes Ave., Pittsburgh PA 15213, USA.
Beau KilmerRAND Drug Policy Research Center, 1776 Main St., Santa Monica, CA 90401, USA.

Funding

Marijuana Legalization: Assessing the Impact of Local Regulatory PoliciesR01DA039293 · NIDA · MULTNOMAH COUNTY HEALTH DEPARTMENT · PI DILLEY, JULIA ANN · 2015 to 2024
$3.6M
NIDA NIH HHS R01 DA039293
6 · The paper itself

Abstract

introductionVoters in eight U.S. states have passed initiatives to legalize large-scale commercial production of cannabis for non-medical use. All plan or require some form of "seed-to-sale" tracking systems, which provide a view of cannabis market activity at a heretofore unimagined level of detail. Legal markets also create a range of new matters for policy makers to address. DATA: Publicly available data were obtained on approximately 45 million individually priced items purchased in the 35 million retail transactions that took place during the first two and a half years of Washington State's legal cannabis market. Records include product type (flower, extract, lotion, liquid edible, etc.), product name, price, and potency with respect to multiple cannabinoids, notably THC and CBD. Items sold can be traced back up the supply chain through the store to the processor and producer, to the level of identifying the specific production batch and mother plant, the firm that tested the product, and test results.

methodData visualization methods are employed to describe spatial-temporal patterns of multiple correlated attributes (e.g., price and potency) broken down by product. Text-analytic methods are used to subdivide the broad category of "extracts for inhalation" into more homogeneous sub-categories. To understand the competitiveness of the legal cannabis market in Washington we calculate the Herfindahl-Hirschman index (HHI) for processors and retailers.

resultsCannabis prices fell steadily and proportionally at the processor and retailer levels. Retail and wholesale price maintained a roughly 3:1 ratio for multiple product types after some initial fluctuations. Although a wide range of edibles are sold, they account for a modest share of consumer spending; extracts for inhalation are a larger and heterogeneous market segment. The HHI indicates the cannabis market is highly competitive at the processor level, but less so for retail markets at the county level.

conclusionsWashington's state-legal cannabis market is diverse and rapidly evolving in terms of pricing, products, and organization. Post-legalization, researchers and policy makers may need to think in terms of a family of cannabis products, akin to how we think of new psychoactive substances and amphetamine-type stimulants, not a single drug "cannabis."

Indexed as

Big DataCommerceHumansLegislation, DrugMarijuana UseWashingtonCannabisDrug policyExtractsLegalizationPotencyPrices

Identifiers

PMID29709847
PMCPMC6948109

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.